143 related articles for article (PubMed ID: 36356831)
21. Targeted Inhibition of LPL/FABP4/CPT1 fatty acid metabolic axis can effectively prevent the progression of nonalcoholic steatohepatitis to liver cancer.
Yang H; Deng Q; Ni T; Liu Y; Lu L; Dai H; Wang H; Yang W
Int J Biol Sci; 2021; 17(15):4207-4222. PubMed ID: 34803493
[No Abstract] [Full Text] [Related]
22. Antagonizing STK25 Signaling Suppresses the Development of Hepatocellular Carcinoma Through Targeting Metabolic, Inflammatory, and Pro-Oncogenic Pathways.
Kurhe Y; Caputo M; Cansby E; Xia Y; Kumari S; Anand SK; Howell BW; Marschall HU; Mahlapuu M
Cell Mol Gastroenterol Hepatol; 2022; 13(2):405-423. PubMed ID: 34624527
[TBL] [Abstract][Full Text] [Related]
23. A Cholecystokinin Receptor Antagonist Halts Nonalcoholic Steatohepatitis and Prevents Hepatocellular Carcinoma.
Tucker RD; Ciofoaia V; Nadella S; Gay MD; Cao H; Huber M; Safronenka A; Shivapurkar N; Kallakury B; Kruger AJ; Kroemer AHK; Smith JP
Dig Dis Sci; 2020 Jan; 65(1):189-203. PubMed ID: 31297627
[TBL] [Abstract][Full Text] [Related]
24. Hepatic NF-kB-inducing kinase (NIK) suppresses mouse liver regeneration in acute and chronic liver diseases.
Xiong Y; Torsoni AS; Wu F; Shen H; Liu Y; Zhong X; Canet MJ; Shah YM; Omary MB; Liu Y; Rui L
Elife; 2018 Aug; 7():. PubMed ID: 30070632
[TBL] [Abstract][Full Text] [Related]
25. Analysis of Liver Microenvironment during Early Progression of Non-Alcoholic Fatty Liver Disease-Associated Hepatocellular Carcinoma in Zebrafish.
Michael C; Martínez-Navarro FJ; de Oliveira S
J Vis Exp; 2021 Apr; (170):. PubMed ID: 33871465
[TBL] [Abstract][Full Text] [Related]
26. Metabolic aspects in NAFLD, NASH and hepatocellular carcinoma: the role of PGC1 coactivators.
Piccinin E; Villani G; Moschetta A
Nat Rev Gastroenterol Hepatol; 2019 Mar; 16(3):160-174. PubMed ID: 30518830
[TBL] [Abstract][Full Text] [Related]
27. Metformin Actions on the Liver: Protection Mechanisms Emerging in Hepatocytes and Immune Cells against NASH-Related HCC.
Zhang Y; Wang H; Xiao H
Int J Mol Sci; 2021 May; 22(9):. PubMed ID: 34065108
[TBL] [Abstract][Full Text] [Related]
28. Imbalance in ALR ubiquitination accelerates the progression of nonalcoholic steatohepatitis to hepatocellular carcinoma.
Zheng M; Ai Z; Guo Y; Chen Y; Xie P; An W
Oncogene; 2023 Jan; 42(4):308-321. PubMed ID: 36434180
[TBL] [Abstract][Full Text] [Related]
29. Hepatocellular carcinoma in a mouse model fed a choline-deficient, L-amino acid-defined, high-fat diet.
Ikawa-Yoshida A; Matsuo S; Kato A; Ohmori Y; Higashida A; Kaneko E; Matsumoto M
Int J Exp Pathol; 2017 Aug; 98(4):221-233. PubMed ID: 28895242
[TBL] [Abstract][Full Text] [Related]
30. Dietary cholesterol promotes steatohepatitis related hepatocellular carcinoma through dysregulated metabolism and calcium signaling.
Liang JQ; Teoh N; Xu L; Pok S; Li X; Chu ESH; Chiu J; Dong L; Arfianti E; Haigh WG; Yeh MM; Ioannou GN; Sung JJY; Farrell G; Yu J
Nat Commun; 2018 Oct; 9(1):4490. PubMed ID: 30367044
[TBL] [Abstract][Full Text] [Related]
31. JCAD Promotes Progression of Nonalcoholic Steatohepatitis to Liver Cancer by Inhibiting LATS2 Kinase Activity.
Ye J; Li TS; Xu G; Zhao YM; Zhang NP; Fan J; Wu J
Cancer Res; 2017 Oct; 77(19):5287-5300. PubMed ID: 28775168
[TBL] [Abstract][Full Text] [Related]
32. Deranged hepatocyte intracellular Ca
Ali ES; Rychkov GY; Barritt GJ
Cell Calcium; 2019 Sep; 82():102057. PubMed ID: 31401389
[TBL] [Abstract][Full Text] [Related]
33. Therapeutic blockade of ER stress and inflammation prevents NASH and progression to HCC.
Boslem E; Reibe S; Carlessi R; Smeuninx B; Tegegne S; Egan CL; McLennan E; Terry LV; Nobis M; Mu A; Nowell C; Horadagoda N; Henstridge DC; Mellett NA; Timpson P; Jones M; Denisenko E; Forrest ARR; Tirnitz-Parker JEE; Meikle PJ; Rose-John S; Karin M; Febbraio MA
Sci Adv; 2023 Sep; 9(37):eadh0831. PubMed ID: 37703359
[TBL] [Abstract][Full Text] [Related]
34. Oncostatin M is overexpressed in NASH-related hepatocellular carcinoma and promotes cancer cell invasiveness and angiogenesis.
Di Maira G; Foglia B; Napione L; Turato C; Maggiora M; Sutti S; Novo E; Alvaro M; Autelli R; Colombatto S; Bussolino F; Carucci P; Gaia S; Rosso C; Biasiolo A; Pontisso P; Bugianesi E; Albano E; Marra F; Parola M; Cannito S
J Pathol; 2022 May; 257(1):82-95. PubMed ID: 35064579
[TBL] [Abstract][Full Text] [Related]
35. Growth-hormone-induced signal transducer and activator of transcription 5 signaling causes gigantism, inflammation, and premature death but protects mice from aggressive liver cancer.
Friedbichler K; Themanns M; Mueller KM; Schlederer M; Kornfeld JW; Terracciano LM; Kozlov AV; Haindl S; Kenner L; Kolbe T; Mueller M; Snibson KJ; Heim MH; Moriggl R
Hepatology; 2012 Mar; 55(3):941-52. PubMed ID: 22031092
[TBL] [Abstract][Full Text] [Related]
36. Fatty acid elongation in non-alcoholic steatohepatitis and hepatocellular carcinoma.
Kessler SM; Simon Y; Gemperlein K; Gianmoena K; Cadenas C; Zimmer V; Pokorny J; Barghash A; Helms V; van Rooijen N; Bohle RM; Lammert F; Hengstler JG; Mueller R; Haybaeck J; Kiemer AK
Int J Mol Sci; 2014 Apr; 15(4):5762-73. PubMed ID: 24714086
[TBL] [Abstract][Full Text] [Related]
37. Contribution of organokines in the development of NAFLD/NASH associated hepatocellular carcinoma.
Vachher M; Bansal S; Kumar B; Yadav S; Arora T; Wali NM; Burman A
J Cell Biochem; 2022 Oct; 123(10):1553-1584. PubMed ID: 35818831
[TBL] [Abstract][Full Text] [Related]
38. JMJD4-demethylated RIG-I prevents hepatic steatosis and carcinogenesis.
Li Z; Zhou Y; Jia K; Yang Y; Zhang L; Wang S; Dong Y; Wang M; Li Y; Lu S; Zhang W; Zhang L; Fan Y; Zhang D; Li N; Yu Y; Cao X; Hou J
J Hematol Oncol; 2022 Nov; 15(1):161. PubMed ID: 36333807
[TBL] [Abstract][Full Text] [Related]
39. Activation of pluripotent genes in hepatic progenitor cells in the transition of nonalcoholic steatohepatitis to pre-malignant lesions.
Xu G; Ye J; Liu XJ; Zhang NP; Zhao YM; Fan J; Liu XP; Wu J
Lab Invest; 2017 Oct; 97(10):1201-1217. PubMed ID: 28869588
[TBL] [Abstract][Full Text] [Related]
40. The different expression of tumor suppressors, RASSF1A, RUNX3, and GSTP1, in patients with alcoholic steatohepatitis (ASH) vs non-alcoholic steatohepatitis (NASH).
Jia Y; Ji P; French B; Tillman B; French SW
Exp Mol Pathol; 2019 Jun; 108():156-163. PubMed ID: 30951700
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
